Related Experiment Videos
Nucleic acid aptamers as adjuncts to vaccine development.
Kristian C D Becker1, Richard C Becker
1Boston University, College of Arts and Sciences, 725 Commonwealth Avenue, Boston, MA 02215, USA. Becke021@mc.duke.edu
Current Opinion in Molecular Therapeutics
|April 14, 2006
Summary
Nucleic acid aptamers, which are DNA or RNA molecules, offer advantages over antibodies for molecular recognition. Despite their potential, only one aptamer is approved for human use, though clinical trials show promise.
Area of Science:
- Biochemistry
- Molecular Biology
- Biotechnology
Background:
- Nucleic acid aptamers are selected RNA or DNA oligonucleotides that bind specific targets with high affinity and specificity.
- They exhibit a 'lock and key' mechanism, enabling discrimination between similar molecules or protein states.
- Aptamers present chemical, biological, and manufacturing advantages over traditional antibodies.
Purpose of the Study:
- To highlight the unique properties and advantages of nucleic acid aptamers.
- To discuss the current status of aptamer development and clinical applications.
- To explore the emerging potential of aptamers in diverse therapeutic and diagnostic fields.
Main Methods:
- Selection and synthesis of RNA or DNA aptamers against specific molecular targets.
- Characterization of aptamer binding affinity and specificity.
- Evaluation of aptamers in preclinical and clinical settings.
Main Results:
- Aptamers demonstrate high specificity, distinguishing between closely related molecules.
- Several aptamer-based therapeutics are in Phase I and II clinical trials for various indications.
- One aptamer is approved for treating wet age-related macular degeneration.
Conclusions:
- Nucleic acid aptamers offer significant advantages over antibodies in molecular recognition.
- Despite limited current clinical use, aptamers show immense potential across various applications.
- Aptamers are poised to revolutionize patient care in areas like imaging, therapeutics, and diagnostics.